肿瘤防治研究2025，Vol.52Issue(2)：98-102,5.DOI:10.3971/j.issn.1000-8578.2025.24.1033
HR阳性HER2低表达晚期乳腺癌治疗研究进展:2024 ASCO会议乳腺癌研究热点解读
Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer:Interpretation of Breast Cancer Research Hotspots in 2024 ASCO
摘要
Abstract
HR-positive HER2-low breast cancer is a new hotspot therapeutic subtype,accounting for approximately 53.7%of all breast cancers.Patients with this type of cancer tend to have a high rate of lymph node metastasis and poor sensitivity to neoadjuvant chemotherapy and conventional anti-HER2 therapy,and exploring therapeutic strategies for this subtype of patient is a current clinical challenge.Therapeutic strategies for HR-positive HER2-low breast cancer are constantly being updated,including CDK4/6 inhibitors across the lines of therapy,and next-generation antibody-drug conjugates such as T-DXd.With the accumulation of high-level evidence-based evidence for HR-positive HER2-low breast cancer in the future,the research data will provide more practical support for precise diagnosis and treatment,thereby improving the prognosis of patients with HR-positive HER2-low breast cancer.关键词
HR阳性/HER2低表达/CDK4/6抑制剂/T-DXd/乳腺癌Key words
HR-positive/HER2-low ex-pression/CDK4/6 inhibitors/T-DXd/Breast cancer分类
临床医学引用本文复制引用
马艺文,徐君南,孙涛..HR阳性HER2低表达晚期乳腺癌治疗研究进展:2024 ASCO会议乳腺癌研究热点解读[J].肿瘤防治研究,2025,52(2):98-102,5.基金项目
沈阳市乳腺癌临床医学研究中心资助课题(2020-48-3-1) （2020-48-3-1）
沈阳市科学技术计划公共卫生研发专项(22-321-31-04) Shenyang Breast Cancer Clinical Medical Research Center(No.2020-48-3-1) （22-321-31-04）
Shenyang Public Health R&D Special Project(No.22-321-31-04) （No.22-321-31-04）
